scholarly journals ALZHEIMER’S DISEASE - UNDERSTANDING SIDDHA MEDICINE LOOMS IN SPECIAL REFERENCE WITH MATA ALIVU

2020 ◽  
Vol p4 (06) ◽  
pp. 2486-2493
Author(s):  
Jenefa Rose Priya. T
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Medical Intervention ◽  
Traditional Healing ◽  
Systemic Review ◽  
Wide Range ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
The Brain ◽  
Disease Understanding

Alzheimer's disease (AD), an unceasing progressive neurological disorder of the brain, sorted below the umbrella term dementia named by German Dr. Aloes Alzheimer in 1906. AD is the most typical drawback of aged, found to mount worldwide, poignant with an approximate of thirty million people. The chief common reason behind AD lands up in nuisance with recollection, thoughts, orientation and behaviour that destruct and shrinks the brain. Presently several disease modifying agents, anticholinesterases outline the foremost dwell among the treatment of AD. However, these medications tend to slower the ill health pro-gression. Further researches are going on rapidly for better manifold innovative cure target. In order to per-suade them, this systemic review is carried with the objective to share the responsibility of Siddha’s insight in comprehending the symptoms (Kuṟikuṇaṅkaḷ), and traditional healing (Maruttuvam) rendering integrable pertinence to manage AD. As Siddha Medicine, a foremost traditional medicine of India describes the use of a wide range of medical intervention of assorted diseases. This ample paradigm information could be used for discrete medicine crusade progression, thereby providing newer purposeful edge for AD.

Lifestyle intervention to prevent Alzheimer’s disease

2020 ◽  
Vol 31 (8) ◽  
pp. 817-824 ◽  
Author(s):  
Yi Ko ◽  
Soi Moi Chye
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Lifestyle Intervention ◽  
Social Engagement ◽  
Treatment Options ◽  
Cognitive Stimulation ◽  
Systemic Review ◽  
Lifestyle Interventions ◽  
Alternative Approaches ◽  
The Brain

AbstractAlzheimer’s disease (AD) is the most common neurodegenerative disease that leads to significant morbidities in elderly. The major pathological hallmark of AD is beta-amyloid plaques (Aβ) and intracellular neurofibrillary tangles (NFTs) deposition in hippocampus of the brain. These abnormal protein deposition damages neuronal cells resulting in neurodegeneration and cognitive decline. As a result of limited treatment options available for this disease, there is huge economic burden for patients and social health care system. Thus, alternative approaches (lifestyle intervention) to prevent this disease are extremely important. In this systemic review, we summarized epidemiological evidence of lifestyle intervention and the mechanisms involved in delaying and/or preventing AD. Lifestyle interventions include education, social engagement and cognitive stimulation, smoking, exercise, depression and psychological stress, cerebrovascular disease (CVD), hypertension (HTN), dyslipidaemia, diabetes mellitus (DM), obesity and diet. The methods are based on a literature review of available sources found on the research topic in four acknowledged databases: Web of Science, Scopus, Medline and PubMed. Results of the identified original studies revealed that lifestyle interventions have significant effects and our conclusion is that combination of early lifestyle interventions can decrease the risk of developing AD.

scholarly journals P2-298: Assessing the economic value of potential disease-modifying agents in Alzheimer's disease using simulation

2013 ◽  
Vol 9 ◽  
pp. P467-P467
Author(s):  
Denis Getsios ◽  
Shien Guo ◽  
Nikhil Revankar ◽  
Linus Jonsson ◽  
Peter Neumann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Economic Value ◽  
Disease Modifying ◽  
Disease Modifying Agents

scholarly journals A IS FOR AMYLOID

2020 ◽  
pp. 1-2
Author(s):  
D.J. Selkoe
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Infectious Diseases ◽  
Task Force ◽  
Modern Medicine ◽  
Disease Modifying ◽  
The Brain ◽  
The Eu

In the age of COVID-19, we are reminded that despite the enormous strides modern medicine has made against acute infectious pathogens, we can still be overwhelmed. And in the field of chronic non-infectious diseases of the brain, we, too, have been traveling a long and unpredictable road. For years, there has been a sense of pessimism about the halting march toward disease-modifying treatments for Alzheimer’s disease. But recent events may have begun to part the clouds. In this issue of JPAD, Aisen et al. (1), representing the EU/US CTAD 2019 Task Force, provide a thoughtful perspective on progress in certain anti-amyloid trials and the resultant lessons for our next steps toward success.

Taking the Next Steps in the Treatment of Alzheimer's Disease: Disease-Modifying Agents

CNS Spectrums ◽  
2008 ◽  
Vol 13 (S3) ◽  
pp. 11-14
Author(s):  
Stephen Salloway
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neurodegenerative Disorder ◽  
Disease Process ◽  
The United States ◽  
Disease Modification ◽  
Disease Modifying ◽  
New Treatment ◽  
Disease Modifying Agents ◽  
Disease Modifying Treatment

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the United States and the number of AD patients is increasing at an alarming rate. There is no cure for AD and the currently available treatments are symptomatic, providing only limited effects on disease pathophysiology and progression. An overwhelming need exists for therapies that can slow or halt this debilitating disease process. Disease modification in AD has been defined from patient-focused, regulatory, and neurobiological perspectives. The latter two of these perspectives rely largely on an interruption of the disease process and a clear demonstration of this interruption. As defined by Cummings, a disease-modifying treatment is a “pharmacologic treatment that retards the underlying process of AD by intervening in the neurobiological processes that constitute the pathology and pathophysiology of the disease and lead to cell death or dysfunction.” By this definition, the burden of confirmatory study is placed on any new treatment for which the claim of “disease modification” is to be made (Slide 1).

scholarly journals Alzheimer‘s disease: exploring nature’s ‘medicinal chest’ for new therapeutic agents

2020 ◽  
Vol 11 (1) ◽  
pp. 201-208
Author(s):  
Anthony Tsarbopoulos
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Medicinal Plants ◽  
Therapeutic Agents ◽  
Lead Compounds ◽  
Age Related ◽  
Aging Properties ◽  
Disease Modifying ◽  
Disease Modifying Agents

AbstractNatural products have served humanity as a valuable source for the discovery and development of therapeutic agents. In addition, these phytochemicals can function as lead compounds for the development of synthetic analogs aimed at treating human diseases. In our aging society, Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a significant and progressive loss of memory and other cognitive functions. As society demographics change, the predominance of AD and other age-related dementias is increasing, with concurrent financial and societal costs.AD represents one of the most remarkable scientific challenges for drug discovery as the search for effective disease-modifying agents has been unsuccessful. Medicinal plants have been used for their “anti-aging” properties, and cognitive enhancing properties. In the past decades, natural products have been studied for their anti-AD properties, and their potential for developing therapeutic agents against several molecular targets has been evaluated. This insight evaluates the prospects of medicinal plants for providing disease-modifying, as well as disease-preventing, agents for AD.

2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents

2012 ◽  
Vol 58 ◽  
pp. 519-532 ◽  
Author(s):  
Stefano Rizzo ◽  
Andrea Tarozzi ◽  
Manuela Bartolini ◽  
Gregory Da Costa ◽  
Alessandra Bisi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Modifying ◽  
Disease Modifying Agents

scholarly journals Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design

2007 ◽  
Vol 34 (S1) ◽  
pp. S103-S108 ◽  
Author(s):  
Nathan Herrmann
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nmda Receptor ◽  
Caregiver Burden ◽  
Trial Design ◽  
Cholinesterase Inhibitors ◽  
Nmda Receptor Antagonist ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
Complete Dependence

Moderate to severe Alzheimer's disease (AD) is characterized by increasing cognitive, functional, and behavioural dysfunction that results in increased caregiver burden and, eventually, complete dependence. Despite its significance as a societal health problem, there are few treatment trials of cognitive enhancers or disease modifying agents for this stage of illness. Studies suggest the cholinesterase inhibitors, especially donepezil, may provide benefit. Several studies provide support for the use of the NMDA receptor antagonist memantine as monotherapy or added to a cholinesterase inhibitor for moderate to severe AD. While there are no published guidelines for the treatment of moderate to severe AD, these studies do provide guidance for recommendations for study design and outcome measures. Such studies are urgently needed.

Sign in / Sign up

Export Citation Format

Share Document